{"id":"pivmecillinam-augmentin","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pivmecillinam works by disrupting peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. The combination with augmentin (amoxicillin/clavulanic acid) provides broader spectrum coverage by protecting the beta-lactam from enzymatic degradation via clavulanic acid's beta-lactamase inhibition, allowing activity against beta-lactamase-producing organisms.","oneSentence":"Pivmecillinam is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while augmentin (amoxicillin/clavulanic acid) combines a beta-lactam with a beta-lactamase inhibitor to overcome resistance.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:30.797Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial urinary tract infections"},{"name":"Lower respiratory tract infections"},{"name":"Skin and soft tissue infections"}]},"trialDetails":[{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT06709196","phase":"PHASE4","title":"Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-01-07","conditions":"Cystectomy, Bladder Cancer Requiring Cystectomy, Postoperative Infections","enrollment":248},{"nctId":"NCT05224401","phase":"PHASE3","title":"Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs","status":"RECRUITING","sponsor":"Lund University","startDate":"2023-05-29","conditions":"Urinary Tract Infections, Bacteremia, Antibiotic Resistant Infection","enrollment":330},{"nctId":"NCT03228108","phase":"PHASE4","title":"Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-04-03","conditions":"Complication, Infection, Prostate Cancer","enrollment":1538}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Selexid","Amoxicillin/clavulanic acid"],"phase":"marketed","status":"active","brandName":"Pivmecillinam/augmentin","genericName":"Pivmecillinam/augmentin","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pivmecillinam is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while augmentin (amoxicillin/clavulanic acid) combines a beta-lactam with a beta-lactamase inhibitor to overcome resistance. Used for Bacterial urinary tract infections, Lower respiratory tract infections, Skin and soft tissue infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}